Scholarlink

Purpose of Review <p>Renal cell carcinoma (RCC) is a prevalent and increasingly diagnosed malignancy associated with high mortality and recurrence rates. Traditional diagnostic and therapeutic approaches have limitations due to the disease’s molecular heterogeneity. This review aims to explore how the integration of omics sciences—genomics, transcriptomics, proteomics, and metabolomics—can enhance the diagnosis, prognosis, and treatment of RCC.</p> Recent Findings <p>Genomic analyses have uncovered critical mutations, including VHL, PBRM1, and BAP1, which support improved risk stratification and the development of targeted therapies. Transcriptomic and spatial transcriptomic studies have provided deeper insights into RCC heterogeneity and tumor microenvironment dynamics. Proteomic investigations have revealed potential biomarkers, while metabolomic approaches have highlighted RCC-specific metabolic shifts. Despite these advancements, several challenges persist, including intratumoral heterogeneity, difficulties in multi-omics data integration, and the limited clinical validation of biomarkers.</p> Summary <p>Omics-driven approaches hold significant promise for advancing precision medicine in RCC. These technologies can facilitate earlier diagnosis, guide individualized therapies, and enhance prognostic evaluations. Future research must focus on validating multi-omic biomarkers and leveraging artificial intelligence to manage complex datasets, thereby supporting more informed clinical decision-making and personalized treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multiomics in Renal Cell Carcinoma: Current Landscape and Future Directions for Precision Medicine

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月26日

查看全文
  • Filippo Gavi,
  • Maria Chiara Sighinolfi,
  • Giuseppe Pallotta,
  • Simone Assumma,
  • Enrico Panio,
  • Daniele Fettucciari,
  • Antonio Silvestri,
  • Pierluigi Russo,
  • Riccardo Bientinesi,
  • Nazario Foschi,
  • Filippo Turri,
  • Umberto Carbonara,
  • Chiara Ciccarese,
  • Roberto Iacovelli,
  • Camilla Nero,
  • Bernardo Rocco

摘要

Purpose of Review

Renal cell carcinoma (RCC) is a prevalent and increasingly diagnosed malignancy associated with high mortality and recurrence rates. Traditional diagnostic and therapeutic approaches have limitations due to the disease’s molecular heterogeneity. This review aims to explore how the integration of omics sciences—genomics, transcriptomics, proteomics, and metabolomics—can enhance the diagnosis, prognosis, and treatment of RCC.

Recent Findings

Genomic analyses have uncovered critical mutations, including VHL, PBRM1, and BAP1, which support improved risk stratification and the development of targeted therapies. Transcriptomic and spatial transcriptomic studies have provided deeper insights into RCC heterogeneity and tumor microenvironment dynamics. Proteomic investigations have revealed potential biomarkers, while metabolomic approaches have highlighted RCC-specific metabolic shifts. Despite these advancements, several challenges persist, including intratumoral heterogeneity, difficulties in multi-omics data integration, and the limited clinical validation of biomarkers.

Summary

Omics-driven approaches hold significant promise for advancing precision medicine in RCC. These technologies can facilitate earlier diagnosis, guide individualized therapies, and enhance prognostic evaluations. Future research must focus on validating multi-omic biomarkers and leveraging artificial intelligence to manage complex datasets, thereby supporting more informed clinical decision-making and personalized treatment strategies.